Low NDRG2, regulated by the MYC/MIZ-1 complex and methylation, predicts poor outcomes in DLBCL patients

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma.
• N-Myc downstream-regulated gene 2 (NDRG2) acts as a tumor suppressor, downregulated in many cancers.
• Mechanisms of metabolic changes in DLBCL remain incompletely understood.

Purpose of the Study:

• To investigate the roles of NDRG2, MYC, and Myc-interacting zinc finger protein 1 (MIZ-1) in DLBCL lymphomagenesis.
• To explore the regulatory mechanisms and biological functions of NDRG2, MYC, and MIZ-1 in DLBCL.
• To analyze the association of these genes with cellular metabolism and prognostic significance in DLBCL.

Main Methods:

• Expression analysis of NDRG2, MYC, and MIZ-1 in DLBCL cell lines and human tumor tissues.
• Investigation of NDRG2 methylation and its reversal using 5-Aza-2'-deoxycytidine (5-Aza-CDR).
• Bioinformatics analysis and survival analysis to assess gene associations and prognostic value.

Main Results:

• NDRG2 expression inversely correlated with MYC and MIZ-1 in DLBCL cell lines and tumor tissues.
• MYC and MIZ-1 promoted DLBCL cell proliferation, while NDRG2 induced apoptosis.
• NDRG2 methylation reversal by 5-Aza-CDR downregulated MYC and inhibited DLBCL cell survival; MYC-NDRG2 interaction impacts mTOR-associated energy metabolism.
• NDRG2 and MYC were identified as significant prognostic biomarkers for DLBCL patients.

Conclusions:

• The MYC/MIZ-1 complex interacts with NDRG2 to regulate DLBCL cell proliferation and apoptosis.
• NDRG2, MYC, and MIZ-1 influence DLBCL metabolism and serve as potential prognostic markers.
• Targeting the NDRG2-MYC axis may offer therapeutic strategies for DLBCL.